Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Carcinoma, Neuroendocrine 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 9lutetium Lu 177 dotatate 6cabozantinib 6Nivolumab 5Ipilimumab 4fludarabine 3X-Rays 3Phantoms, Imaging 3Etoposide 3Cyclophosphamide 3CTLA-4 Antigen 3pembrolizumab 2olaparib 2aldesleukin 2Lutetium-177 2Lutetium 2Irinotecan 2Cisplatin 2Carboplatin 2trametinib 1tivozanib 1tipifarnib 1selpercatinib 1repotrectinib 1pazopanib 1gallium Ga 68 dotatate 1gallium 68 PSMA-11 1fluorodopa F 18 1fluorocholine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
belinostat × Endocrine × 30 days × Clear all
NCT06406465 2026-06-05

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡